A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
NCT04617275
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
151
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes
Obesity
Interventions
DRUG:
PF-06882961
OTHER:
Placebo
Sponsor
Pfizer